Muhammad A Memon1, Burcak Karaca2, Rasha Aboelhassan3, Mohsen Barsoum4, Mustafa Erman5, Mert Basaran6, Alper Sevinc7, Djedi Hanene8, Cassandra Slader9, Virginia Pilipovic9, Kerboua Esma10, Bouzid Kamel10. 1. Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. memon@kfshrc.edu.sa. 2. Ege University, Izmir, Turkey. 3. Nasser Institute for Research and Treatment, Cairo, Egypt. 4. National Cancer Institute Cairo University, Giza, Egypt. 5. Hacettepe University, Ankara, Turkey. 6. Istanbul University, Istanbul, Turkey. 7. Department of Medical Oncology, Medical Park Gaziantep Hospital, Gaziantep, Turkey. 8. Anticancer Center, Annaba, Algeria. 9. Novartis Pharma AG, Basel, Switzerland. 10. Centre Pierre et Marie Curie, Alger, Algeria.
Abstract
PURPOSE: Soft tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal neoplasms, accounting for < 1% of all newly diagnosed malignancies. These tumors can occur in almost any anatomic site though they most frequently occur in the extremities. The objective of the study was to describe the epidemiology, treatment paradigm, and real-world outcomes in the clinical management of metastatic STS (mSTS) in the Middle East and North Africa (MEA) region. METHODS: MOON was an observational, multicenter, retrospective patient chart review study which included 200 patients with mSTS in the final analysis. The primary objective of the study is exploratory, so it is presented using descriptive statistics. RESULTS: At the time of presentation, 62.0% patients had metastatic disease, 27.5% had received only their primary diagnosis and 10.0% had experienced a local recurrence. The most frequent STS localizations were lower extremities (74%), trunk (28.5%) and upper extremities (10.5%). Primary tumor was staged as T2b in the majority (60%) of patients. Surgical treatment was performed most often for the primary disease, whereas radiation therapy and chemotherapy were predominantly administered with palliative intent. A total of 38 patients received treatment with pazopanib. Thirteen adverse events (AEs) were attributed to pazopanib in eight patients. CONCLUSION: Adult patients treated for STS have al most equal gender ratio and mostly are middle aged. The majority of patients have metastatic disease and disease progression, and half of the patients died from the disease during the period of evaluation. This study obtained real-life data on the clinical management of STS in MEA countries which could be shared with the medical community.
PURPOSE: Soft tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal neoplasms, accounting for < 1% of all newly diagnosed malignancies. These tumors can occur in almost any anatomic site though they most frequently occur in the extremities. The objective of the study was to describe the epidemiology, treatment paradigm, and real-world outcomes in the clinical management of metastatic STS (mSTS) in the Middle East and North Africa (MEA) region. METHODS: MOON was an observational, multicenter, retrospective patient chart review study which included 200 patients with mSTS in the final analysis. The primary objective of the study is exploratory, so it is presented using descriptive statistics. RESULTS: At the time of presentation, 62.0% patients had metastatic disease, 27.5% had received only their primary diagnosis and 10.0% had experienced a local recurrence. The most frequent STS localizations were lower extremities (74%), trunk (28.5%) and upper extremities (10.5%). Primary tumor was staged as T2b in the majority (60%) of patients. Surgical treatment was performed most often for the primary disease, whereas radiation therapy and chemotherapy were predominantly administered with palliative intent. A total of 38 patients received treatment with pazopanib. Thirteen adverse events (AEs) were attributed to pazopanib in eight patients. CONCLUSION: Adult patients treated for STS have al most equal gender ratio and mostly are middle aged. The majority of patients have metastatic disease and disease progression, and half of the patients died from the disease during the period of evaluation. This study obtained real-life data on the clinical management of STS in MEA countries which could be shared with the medical community.
Authors: E Gortzak; A Azzarelli; J Buesa; V H Bramwell; F van Coevorden; A N van Geel; A Ezzat; A Santoro; J W Oosterhuis; M van Glabbeke; A Kirkpatrick; J Verweij Journal: Eur J Cancer Date: 2001-06 Impact factor: 9.162
Authors: Elisabeth Andritsch; Marc Beishon; Stefan Bielack; Sylvie Bonvalot; Paolo Casali; Mirjam Crul; Roberto Delgado Bolton; Davide Maria Donati; Hassan Douis; Rick Haas; Pancras Hogendoorn; Olga Kozhaeva; Verna Lavender; Jozsef Lovey; Anastassia Negrouk; Philippe Pereira; Pierre Roca; Godelieve Rochette de Lempdes; Tiina Saarto; Bert van Berck; Gilles Vassal; Markus Wartenberg; Wendy Yared; Alberto Costa; Peter Naredi Journal: Crit Rev Oncol Hematol Date: 2016-12-08 Impact factor: 6.312
Authors: William M Mendenhall; Daniel J Indelicato; Mark T Scarborough; Robert A Zlotecki; C Parker Gibbs; Nancy P Mendenhall; Charles M Mendenhall; William F Enneking Journal: Am J Clin Oncol Date: 2009-08 Impact factor: 2.339
Authors: Michael J Wagner; Leo Ismaila Amodu; Mei Sheng Duh; Caroline Korves; Franco Solleza; Stephanie C Manson; José Diaz; Maureen P Neary; George D Demetri Journal: BMC Cancer Date: 2015-03-25 Impact factor: 4.430
Authors: Maroun Bou Zerdan; Paul Meouchy; Nour Abdul Halim; Said Saghieh; Eman Sbaity; Rachid Haidar; Jaber Abbas; Amir Ibrahim; Mohamad Khalifeh; Hazem I Assi Journal: J Int Med Res Date: 2022-03 Impact factor: 1.671